Ulixertinib is a reversible ERK1/2 inhibitor that demonstrates an IC50 value of V600E mutation, it has been reported to reduce the levels of phosphorylated ERK2 and the downstream kinase RSK (IC50s = 4.1 and 0.14 µM, respectively). Ulixertinib has also been shown to inhibit A375 cell proliferation with an IC50 value...

Description: Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors. Target: ERK. Smiles:...